NovaBay Pharmaceuticals to Present New Data on Lead Anti-Infective Compound at the 2009 ICAAC Annual Meeting

San Francisco, CA September 12-15, 2009

EMERYVILLE, Calif., Aug. 21 /PRNewswire-FirstCall/ -- NovaBay Pharmaceuticals, Inc. (NYSE-Amex: NBY), a clinical stage company developing non-antibiotic anti-infective compounds for the treatment or prevention of a wide range of bacterial, viral, and fungal infections, will deliver two poster presentations at the 49th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC) in San Francisco, CA. The two poster presentations will describe results from new studies of NVC-422, an Aganocide compound.
 

  Presentation details are as follows:

  Poster Title:     N,N-dichloro-2,2-dimethyltaurine (NVC-422) has
                    bactericidal activity against antiseptic and
                    antibiotic-resistant Staphylococcus aureus
  Date/Time:        Monday September 14, from 11:15 am to 1:15 pm
                    (Pacific Time)
  Session:          163. Miscellaneous
  Abstract Number:  E-1468
  Location:         Hall B

  Poster Title:     Antimicrobial activity of endogenous and stabilized
                    derivatives of N-chlorotaurines against representative
                    microorganisms in the presence of human plasma, serum
                    and albumin
  Date/Time:        Monday September 14, from 11:15 am to 1:15 pm
                    (Pacific Time)
  Session:          167-New Topical Antibacterial Agents Including Agents
                    against C. difficile
  Abstract Number:  F1-1526
  Location:         Hall B

"These findings support the compelling therapeutic profile of NVC-422 as a broad spectrum antimicrobial agent that carries little potential for resistance through common antiseptic resistance mechanisms," said Dr. Dmitri Debabov, poster co-author and assistant director of microbiology and acting head of biology of NovaBay Pharmaceuticals.
 

About Aganocide Compounds
 

The Aganocide compounds are novel, proprietary, synthetic N-chlorinated antimicrobial molecules specifically designed by NovaBay to mimic the body's natural defense against infection. The Aganocide compounds maintain the biological activities while improving the stability of naturally occurring N-chlorinated antimicrobial molecules. These highly differentiated compounds may deliver the same or better efficacy than currently used antibiotics without contributing to the growing rise of bacterial resistance. In preclinical trials, the Aganocide compounds have shown to be highly effective against bacteria, viruses and fungi. They have also been demonstrated to be effective against bacteria in biofilm, which render most antibiotics ineffective. These compounds have a potentially broad therapeutic index providing a high degree of potency, good tolerability and dosing versatility and flexibility.
 

About NovaBay Pharmaceuticals, Inc.
 

NovaBay Pharmaceuticals is a mid-stage biopharmaceutical company focused on developing its proprietary and patented Aganocide compounds, first-in-class, novel, synthetic anti-infective product candidates that are bioequivalent to the active antimicrobial molecules generated within white blood cells to treat and prevent a wide range of infections without causing resistance. NovaBay has internal development programs aimed at addressing hospital and respiratory infections. The company has a licensing and research collaboration agreement with Alcon, Inc. for use of its Aganocides in the eye, ear and sinus, and in contact lens solutions. NovaBay has entered into an agreement with Galderma S.A. to develop and commercialize Aganocides in acne, impetigo and other dermatological indications. NovaBay and Aganocide are trademarks of NovaBay Pharmaceuticals, Inc. For more information on NovaBay, visit www.novabaypharma.com.
 

Cautionary Information Regarding Forward-Looking Statements
 

The statements in this press release of NovaBay's expectations regarding the Aganocides possessing the characteristics of a broad spectrum antimicrobial agent that carries little potential for resistance and the development and commercialization of its Aganocide compounds through collaborations with corporate partners and other risks relating to NovaBay and its Aganocide compounds, including risks that could cause actual results to differ materially from those projected in the forward-looking statements in this press release, are detailed in NovaBay's Annual Report on Form 10-K, under the caption "Risk Factors" in Item 1A of Part I of that report, which was filed with the Securities and Exchange Commission on March 31, 2009.
 

Source: NovaBay Pharmaceuticals, Inc.

CONTACT: Tom Paulson, Chief Financial Officer of NovaBay
Pharmaceuticals, Inc., +1-510-899-8809, tpaulson@novabaypharma.com; or Media
Relations, Aimee Corso, +1-310-780-2661, acorso@wcpglobal.com for NovaBay
Pharmaceuticals, Inc.
 

Web Site: http://www.novabaypharma.com/
 

Posted: August 2009

View comments

Hide
(web5)